Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DXCM DexCom	$76.40	$83.83	$57.52 ▼ $93.25	$29.96B	1.43	3.64 million shs	3.07 million shs
HRC Hill-Rom	$155.96	$155.74	$93.34 ▼ $156.22	$10.30B	0.55	656,912 shs	N/A
PODD Insulet	$303.55 +9.5%	$299.47	$173.00 ▼ $329.33	$19.51B	1.35	553,722 shs	1.79 million shs
STE STERIS	$236.07 +6.7%	$234.17	$200.98 ▼ $252.79	$21.76B	0.92	689,125 shs	1.17 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DXCM DexCom	0.00%	-5.41%	-8.79%	-9.76%	+10.21%
HRC Hill-Rom	0.00%	0.00%	0.00%	0.00%	0.00%
PODD Insulet	+9.47%	+5.25%	+2.37%	-2.21%	+59.44%
STE STERIS	+6.53%	+4.20%	+1.46%	+4.20%	+1.09%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DXCM DexCom	4.9683 of 5 stars	4.5	5.0	0.0	4.7	3.9	2.5	1.9
HRC Hill-Rom	1.4966 of 5 stars	0.0	0.0	1.7	3.8	0.6	1.7	1.3
PODD Insulet	4.2325 of 5 stars	2.4	4.0	0.0	4.9	2.9	0.8	1.9
STE STERIS	4.8202 of 5 stars	3.4	3.0	4.2	3.8	3.2	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DXCM DexCom	2.95	Moderate Buy	$99.89	30.75% Upside
HRC Hill-Rom	0.00	N/A	N/A	N/A
PODD Insulet	2.84	Moderate Buy	$321.00	5.75% Upside
STE STERIS	2.75	Moderate Buy	$270.33	14.52% Upside

Current Analyst Ratings Breakdown

Latest HRC, DXCM, STE, and PODD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	PODD Insulet	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
8/7/2025	PODD Insulet	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/1/2025	DXCM DexCom	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$106.00
7/31/2025	DXCM DexCom	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/31/2025	DXCM DexCom	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$90.00 ➝ $100.00
7/31/2025	DXCM DexCom	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$99.00 ➝ $102.00
7/31/2025	DXCM DexCom	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$95.00 ➝ $102.00
7/31/2025	DXCM DexCom	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$105.00 ➝ $106.00
7/30/2025	DXCM DexCom	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$93.00 ➝ $98.00
7/22/2025	STE STERIS	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$277.00 ➝ $288.00
7/16/2025	DXCM DexCom	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$95.00 ➝ $100.00

(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DXCM DexCom	$4.03B	7.43	$2.25 per share	33.99	$6.56 per share	11.65
HRC Hill-Rom	$3.02B	3.41	$9.29 per share	16.79	$28.56 per share	5.46
PODD Insulet	$2.07B	10.31	$4.86 per share	62.50	$17.27 per share	17.58
STE STERIS	$5.57B	4.17	$15.21 per share	15.52	$67.33 per share	3.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DXCM DexCom	$576.20M	$1.44	53.06	31.06	1.60	13.29%	30.41%	10.08%	10/23/2025 (Estimated)
HRC Hill-Rom	$248.50M	$3.72	41.92	21.72	N/A	8.23%	23.07%	8.96%	N/A
PODD Insulet	$418.30M	$5.56	54.60	61.08	2.48	18.29%	22.25%	8.29%	N/A
STE STERIS	$614.64M	$6.53	36.15	23.77	N/A	11.61%	14.40%	9.31%	N/A

Latest HRC, DXCM, STE, and PODD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	PODD Insulet	$0.92	$1.17	+$0.25	$0.32	$612.31 million	$649.10 million
8/6/2025	Q1 2026	STE STERIS	$2.32	$2.34	+$0.02	$1.79	$1.36 billion	$1.40 billion
7/30/2025	Q2 2025	DXCM DexCom	$0.45	$0.48	+$0.03	$0.45	$1.13 billion	$1.16 billion
5/14/2025	Q4 2025	STE STERIS	$2.59	$2.74	+$0.15	$1.47	$1.47 billion	$1.48 billion
5/8/2025	Q1 2025	PODD Insulet	$0.81	$1.02	+$0.21	$0.50	$543.20 million	$569.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DXCM DexCom	N/A	N/A	N/A	N/A	N/A
HRC Hill-Rom	$0.96	0.62%	N/A	25.81%	N/A
PODD Insulet	N/A	N/A	N/A	N/A	N/A
STE STERIS	$2.52	1.07%	N/A	38.59%	20 Years

Latest HRC, DXCM, STE, and PODD Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/30/2025	STE STERIS	quarterly	$0.63	1.1%	9/4/2025	9/4/2025	9/26/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DXCM DexCom	0.48	1.52	1.35
HRC Hill-Rom	0.97	1.38	1.05
PODD Insulet	1.21	4.47	3.63
STE STERIS	0.29	1.96	1.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DXCM DexCom	97.75%
HRC Hill-Rom	76.45%
PODD Insulet	N/A
STE STERIS	94.69%

Insider Ownership

Company	Insider Ownership
DXCM DexCom	0.32%
HRC Hill-Rom	0.69%
PODD Insulet	0.39%
STE STERIS	1.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DXCM DexCom	10,300	392.15 million	390.90 million	Optionable
HRC Hill-Rom	10,000	66.05 million	65.59 million	Optionable
PODD Insulet	3,900	70.38 million	70.10 million	Optionable
STE STERIS	17,787	98.37 million	97.32 million	Optionable

HRC, DXCM, STE, and PODD Headlines

Recent News About These Companies

STE Beats on Q1 Earnings and Revenues, Raises '26 Sales View

August 7 at 9:21 AM | zacks.com

Zacks Research Issues Negative Estimate for STERIS Earnings

August 7 at 8:12 AM | marketbeat.com

Steris (STE) Q1 Revenue Rises 8%

August 7 at 2:03 AM | fool.com

Steris reports Q1 adjusted EPS $2.34, consensus $2.26

August 6 at 11:01 PM | msn.com

Steris affirms fiscal 2026 adjusted EPS outlook $9.90-$10.15, consensus $10.04

August 6 at 11:01 PM | msn.com

STERIS (NYSE:STE) Beats Q2 Sales Targets

August 6 at 11:01 PM | finance.yahoo.com

Compared to Estimates, Steris (STE) Q1 Earnings: A Look at Key Metrics

August 6 at 7:32 PM | zacks.com

Steris (STE) Tops Q1 Earnings and Revenue Estimates

August 6 at 6:45 PM | zacks.com

STERIS Announces CFO Resignation and Successor

August 6 at 5:36 PM | tipranks.com

STERIS Announces Financial Results for Fiscal 2026 First Quarter | STE Stock News

August 6 at 5:13 PM | gurufocus.com

STERIS Announces Chief Financial Officer Transition | STE Stock News

August 6 at 5:13 PM | gurufocus.com

STERIS Announces Financial Results for Fiscal 2026 First Quarter

August 6 at 5:12 PM | gurufocus.com

STERIS Announces Chief Financial Officer Transition

August 6 at 5:12 PM | gurufocus.com

STERIS Announces Chief Financial Officer Transition

August 6 at 4:31 PM | globenewswire.com

STERIS Announces Financial Results for Fiscal 2026 First Quarter

August 6 at 4:30 PM | globenewswire.com

Middleton & Co. Inc. MA Acquires 1,670 Shares of STERIS plc (NYSE:STE)

August 6 at 5:46 AM | marketbeat.com

STERIS plc (NYSE:STE) Shares Bought by PNC Financial Services Group Inc.

August 6 at 4:26 AM | marketbeat.com

What To Expect From STERIS’s (STE) Q2 Earnings

August 6 at 2:36 AM | finance.yahoo.com

STERIS plc (NYSE:STE) Given Average Recommendation of "Moderate Buy" by Brokerages

August 6 at 2:20 AM | marketbeat.com

US Bancorp DE Has $5.44 Million Position in STERIS plc (NYSE:STE)

August 5 at 4:21 AM | marketbeat.com

Steris (STE) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

August 4, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Rocket Lab Gets New Street-High Price Target from Citi
By Ryan Hasson | July 16, 2025
View Rocket Lab Gets New Street-High Price Target from Citi
3 Stocks Flying Under the S&P 500 Radar
By Chris Markoch | July 25, 2025
View 3 Stocks Flying Under the S&P 500 Radar
Why Meta’s AI Titan Clusters Are a Game-Changer for Broadcom
By Leo Miller | July 23, 2025
View Why Meta’s AI Titan Clusters Are a Game-Changer for Broadcom
Super Micro Stock May Benefit as Cooling Demand Takes Off
By Gabriel Osorio-Mazilli | July 16, 2025
View Super Micro Stock May Benefit as Cooling Demand Takes Off
This Fund Manager Says You Should Get Out of Tesla and Apple—Now
By Brian O'Connell | July 16, 2025
View This Fund Manager Says You Should Get Out of Tesla and Apple—Now

HRC, DXCM, STE, and PODD Company Descriptions

DexCom NASDAQ:DXCM

$76.40 0.00 (0.00%)

Closing price 08/7/2025 04:00 PM Eastern

Extended Trading

$76.63 +0.23 (+0.30%)

As of 08/7/2025 07:58 PM Eastern

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Hill-Rom NYSE:HRC

Hill-Rom Holdings, Inc. operates as a medical technology company. The firm focuses on patient care solutions that improve clinical and economic outcomes. It operates through the following segments: Patient Support System, Front Line Care and Surgical Solutions. The Patient Support Systems segment provides bed frames and surfaces, mobility and clinical workflow solutions. The Front Line Care segment offers respiratory care products and sells medical diagnostic equipment and a diversified portfolio of devices. The Surgical Solutions segment supplies surgical products including tables, lights, pendants, positioning devices, various other surgical products and accessories. The company was founded by William A. Hillenbrand on August 7, 1969 and is headquartered in Chicago, IL.

Insulet NASDAQ:PODD

$303.55 +26.25 (+9.47%)

Closing price 08/7/2025 04:00 PM Eastern

Extended Trading

$303.69 +0.14 (+0.05%)

As of 08/7/2025 07:42 PM Eastern

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

STERIS NYSE:STE

$236.07 +14.86 (+6.72%)

Closing price 08/7/2025 03:59 PM Eastern

Extended Trading

$236.24 +0.17 (+0.07%)

As of 08/7/2025 07:26 PM Eastern

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier, sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and electric-powered dental instruments, infection control products, conscious sedation, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time